Eli Lilly and Company
LLY · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $10,590,000 | $5,240,400 | $6,244,800 | $5,581,700 |
| Dep. & Amort. | $1,766,600 | $1,527,300 | $1,522,500 | $1,547,600 |
| Deferred Tax | -$2,683,100 | -$2,341,000 | -$2,185,200 | -$802,300 |
| Stock-Based Comp. | $645,600 | $628,500 | $371,100 | $342,800 |
| Change in WC | -$5,385,000 | -$3,055,000 | -$800 | -$1,012,600 |
| Other Non-Cash | $3,883,800 | $2,239,900 | $1,633,300 | $1,708,700 |
| Operating Cash Flow | $8,817,900 | $4,240,100 | $7,585,700 | $7,365,900 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$5,057,800 | -$3,447,600 | -$1,854,300 | -$1,309,800 |
| Net Acquisitions | -$947,700 | -$1,044,300 | -$327,200 | -$747,400 |
| Inv. Purchases | -$775,800 | -$829,000 | -$707,600 | -$1,013,400 |
| Inv. Sales/Matur. | $522,500 | $700,300 | $463,600 | $847,400 |
| Other Inv. Act. | -$3,042,700 | -$2,532,100 | -$1,337,400 | -$644,300 |
| Investing Cash Flow | -$9,301,500 | -$7,152,700 | -$3,762,900 | -$2,867,500 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $8,901,100 | $8,649,900 | -$62,000 | $501,400 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$2,500,000 | -$750,000 | -$1,500,000 | -$1,250,000 |
| Dividends Paid | -$4,680,400 | -$4,069,300 | -$3,535,800 | -$3,086,800 |
| Other Fin. Act. | -$490,600 | -$335,000 | -$308,900 | -$295,900 |
| Financing Cash Flow | $1,230,100 | $3,495,600 | -$5,406,700 | -$4,131,300 |
| Forex Effect | -$296,700 | $168,600 | -$167,600 | -$205,700 |
| Net Chg. in Cash | $449,800 | $751,600 | -$1,751,500 | $161,400 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $2,818,600 | $2,067,000 | $3,818,500 | $3,657,100 |
| End Cash | $3,268,400 | $2,818,600 | $2,067,000 | $3,818,500 |
| Free Cash Flow | $414,300 | -$3,152,000 | $4,600,400 | $5,387,500 |